Drug intelligence / Profile preview

NRP409

Development stage: Preclinical
Lead developer: Takeda
Modality: Small Molecules
Administration: Oral

Overview

NRP409 is a Carrierwave™ triiodothyronine (T3) hormone developed as a treatment for primary hypothyroidism. It was designed to reduce the variability of hormone availability while minimizing safety risks associated with other T3-based therapies. New River Pharmaceuticals believed it would represent the first significant improvement in thyroid hormone replacement therapy in approximately half a century.

Targets

THRA (Thyroid hormone receptor alpha)THRB (Thyroid hormone receptor beta)THR (Thyroid hormone receptor)

Beyond the preview

Go deeper on NRP409.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NRP409.